Positive efficacy and safety data were observed at 3 months after a single injection of K8 in this study conducted at the University of Kentucky.

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

A post-hoc analysis assessed micronutrient supplementation, including lutein and zeaxanthin, to determine if it slows progression of noncentral geographic atrophy. Share on Facebook. Opens in a ...

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

Two reading metrics outperform 2 existing reading metrics for determining functional decline in patients with geographic atrophy.

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Bubendorfer-Vorwerk H, Schuster A, Lewis P, Picker N, Finger R (eds.): Prevalence of geographic atrophy in Germany—an assessment derived from literature-based estimates and claims data results.